Detalhe da pesquisa
1.
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 20(6): 862-876, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31076365
2.
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Lancet Oncol
; 19(8): 1117-1125, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30026000
3.
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Gynecol Oncol
; 140(3): 443-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26740259
4.
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
Int J Gynecol Cancer
; 26(5): 898-905, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27206218
5.
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Gynecol Oncol
; 136(1): 37-42, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25434635
6.
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.
Cancer
; 120(3): 335-43, 2014 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24127346
7.
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Clin Cancer Res
; 29(20): 4068-4075, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37581616
8.
A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.
MAGMA
; 24(2): 85-96, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21203797
9.
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
J Clin Oncol
; 38(32): 3753-3762, 2020 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822286
10.
Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.
Gynecol Oncol
; 134(1): 6-9, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24952408
11.
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
J Clin Oncol
; 37(32): 2968-2973, 2019 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31173551
12.
Discussion: session 1.
Future Oncol
; 9(12 Suppl): 25-7, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24195527
13.
Discussion: session 2.
Future Oncol
; 9(12 Suppl): 37-9, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24195529
14.
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
J Clin Oncol
; 34(21): 2516-25, 2016 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27269942
15.
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
J Clin Oncol
; 32(30): 3374-82, 2014 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25225436
16.
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
Expert Rev Anticancer Ther
; 10(6): 795-805, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20553205